In vitro evaluation shows improved biomineralization and drug release in CA/HA membranes, indicating potential for reducing inflammation.
Implant-associated acute inflammation remains a major challenge in orthopedic, dental, and maxillofacial applications, often impairing osseointegration and leading to early implant failure. In this study, multifunctional cellulose acetate/hydroxyapatite–dexamethasone (CA/HA–DEXA) composite membranes were developed to locally modulate inflammation while supporting early bone–implant interactions. Cellulose acetate provides a flexible matrix, hydroxyapatite enhances bioactivity and osteoconductivity, and dexamethasone acts as an anti-inflammatory agent. The membranes exhibited composition-dependent swelling and drug release behavior. The swelling degree decreased from ~11% for pristine CA to ~5% for the highest HA–DEXA loading, indicating a denser structure with restricted water uptake. Dexamethasone release showed a biphasic profile, with cumulative release reaching ~68%, ~88%, and ~93% for 0.5%, 1%, and 2% HA–DEXA loadings after 72 h, respectively. In vitro evaluation indicated improved biomineralization for CA/HA–DEXA membranes compared to neat CA, attributed to the role of hydroxyapatite as a nucleation promoter. These findings suggest that CA/HA–DEXA composite membranes represent a promising strategy for controlling early inflammatory responses while supporting bone regeneration at the implant interface.
No takes yet. Share an insight, caveat, or question.
Voicu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: